-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroThera Labs enrolls 26 patients in SCI-210 autism trial in Israel

PUBT·08/31/2026 20:00:34
Listen to the news
NeuroThera Labs enrolls 26 patients in SCI-210 autism trial in Israel
  • Neurothera Labs reported faster enrollment in its SCI-210 autism trial, a placebo-controlled study in children with ASD.
  • No results have been presented; the update focused on recruitment progress toward the planned 60 participants.
  • The study is testing whether SCI-210 can improve autism-related symptoms versus CBD alone, supporting a potential differentiated therapy.
  • 26 children have enrolled; treatment lasts 20 weeks, with initial commercialization targeted for Israel if development succeeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurothera Labs Inc. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608311600TNWSWRCACNPR_____1k98FqlyZ) on August 31, 2026, and is solely responsible for the information contained therein.